Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus (CROSBI ID 167997)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Frobe, Ana ; Jones, Glenn ; Jakšić, Blanka ; Bokulić, Tomislav ; Budanec, Mirjana ; Mrčela, Iva ; Staničić- Rokotov, Dinko ; Hrabar, Davor ; Bolanča, Ante ; Rosenblatt, Eduardo et al. Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus // Diseases of the esophagus, 22 (2009), 6; 513-518. doi: 10.1111/j.1442-2050.2009.00958.x

Podaci o odgovornosti

Frobe, Ana ; Jones, Glenn ; Jakšić, Blanka ; Bokulić, Tomislav ; Budanec, Mirjana ; Mrčela, Iva ; Staničić- Rokotov, Dinko ; Hrabar, Davor ; Bolanča, Ante ; Rosenblatt, Eduardo ; Kusić, Zvonko

engleski

Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus

Intraluminal high dose rate brachytherapy (ILHDR BT) is one of several effective modalities for palliation of advanced esophageal cancer. Thirty patients with endoscopic-proven, mostly locally advanced, squamous cell carcinoma of the esophagus, not involving the gastroesophageal junction and without distant metastases, were included in this analysis. Twenty- nine patients received two ILHDR BT sessions of 8 Gy within a week and one patient received only one session. All patients were followed monthly. Outcomes included quality of life (QOL), symptoms control: dysphagia, regurgitation, odynophagia, and chest or back pain, as well as, overall survival. Through 4 months of follow-up, QOL was statistically improved (having lowered scores) in regards to feelings (P= 0.013), sleeping (P= 0.032), eating (P= 0.020), and social life (P= 0.002). The most significantly improved symptom was dysphagia (P < 0.006), with a reduction of 0.52 units or one-half grade. Regurgitation, odynophagia, and pain were lower during follow-up but were not statistically significant. The median overall survival from death of any cause was 165 days (with a 95% confidence interval of 128–195 days). In conclusion, ILHDR BT of advanced squamous esophageal cancer consisting of two out- patient procedures is very successful in achieving the primary objectives of the patients to reduce dysphagia and improve QOL.

brachytherapy high dose rate ; dysphagia ; esophageal cancer ; palliative care ; quality of life

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

22 (6)

2009.

513-518

objavljeno

1120-8694

1442-2050

10.1111/j.1442-2050.2009.00958.x

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost